Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06958211 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
A Phase 3 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
- 20
- Study locations
NCT06958211 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 550 participants, roughly in line with the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The trial reports 20 study locations across 6 states.
The verdict
NCT06958211, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Study Locations (20)
California
- Investigative Site US262 - Encino
- Investigative Site US222 - Fountain Valley
- Investigative Site US211 - Los Angeles
- Investigative Site US237 - Los Angeles
- Investigative Site US234 - Northridge
- Investigative Site US250 - Santa Ana
Florida
- Investigative Site US208 - Boca Raton
- Investigative Site US203 - Hialeah
- Investigative Site US258 - Jacksonville
- Investigative Site US206 - Maitland
- Investigative Site US223 - Miami
Arizona
- Investigative Site US215 - Phoenix
- Investigative Site US261 - Phoenix
- Investigative Site US221 - Scottsdale
- Investigative Site US240 - Tucson
Alabama
- Investigative Site US257 - Birmingham
- Investigative Site US218 - Birmingham
- Investigative Site US239 - Montgomery
Colorado
- Investigative Site US244 - Castle Rock
Connecticut
- Investigative Site US252 - Cromwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2027-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06958211
The ClinicalTrials.gov registry entry for NCT06958211 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT06958211 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06958211 about?
NCT06958211 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
What is the current status of trial NCT06958211?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2025-06-12. Estimated completion is 2027-07-11.
What conditions does trial NCT06958211 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06958211?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT06958211?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06958211 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.